| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| Allogeneic bone marrow transplantation for aplastic anemia |
|
International Journal of Hematology |
Aplastic Anemia |
| Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades |
|
Blood Advances |
Aplastic Anemia |
| Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy |
|
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
| Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision-Making |
|
American Journal of Hematology |
Aplastic Anemia |
| Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia |
|
Blood |
Aplastic Anemia |
| Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia |
|
Blood |
Aplastic Anemia |
